Clinical Trial: A Study to Evaluate Safety and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 17 Months

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK338924

Brief Summary: The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of the respiratory syncytial virus (RSV) candidate vaccine when first administered via intramuscular (IM) injection according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 17 months.